This study sought to evaluate the inhibitory effect of pulsed electromagnetic field (PEMF) therapy on bone resorption in a mouse model of lipopolysaccharide (LPS)-induced osteoporosis. A total of 40 mice were divided into four groups: control, LPS, LPS + alendronate, and LPS + PEMF. Blood and spleen samples were analyzed using RT-PCR and ELISA, while calvaria and femurs were assessed by micro-computed tomography (CT) and histological analysis. Serum analysis revealed that, compared with the control group, calcium levels in the PEMF group showed no significant difference, but alkaline phosphatase (ALP) levels were significantly increased, whereas tartrate-resistant acid phosphatase (TRAP) levels were significantly decreased. Moreover, blood cytokine analysis showed reduced expression of TNF-α and IL-1β and increased expression of BMP-2 in the PEMF group. Spleen tissue analysis further demonstrated significant upregulation of IFN-γ and IL-10 expression in the PEMF group. Micro-CT confirmed that PEMF inhibited femoral bone loss and promoted bone regeneration in calvarial defects. Histological evaluation with hematoxylin and eosin and Masson–Goldner trichrome staining confirmed enhanced bone formation in both the femur and calvaria. In conclusion, PEMF effectively alleviates bone loss and promotes bone regeneration in LPS-induced osteoporosis. Furthermore, PEMF exhibits anti-osteoclastogenic activity by reducing inflammatory cytokines and enhancing IFN-γ and IL-10 expression in the spleen.

Background: Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. Gamma (γ) oscillations are closely linked to learning and memory, and recent interest has grown around Gamma ENtrainment Using Sensory stimulation (GENUS) as a non-invasive neuromodulation strategy. However, the therapeutic impact of vibrotactile gamma stimulation under varying physical parameters such as acceleration remains underexplored. Methods: Differentiated SH-SY5Y cells were treated with amyloid-β (Aβ) and exposed to vibrotactile stimulation at 2.2 or 4.0 m/s². In vivo, male C57BL/6N mice (7 weeks old, 35 g) were administered scopolamine to induce neurotoxicity and randomly assigned to sham, scopolamine, donepezil, or vibrotactile stimulation groups (n = 10 each). Behavioral tests, biochemical assays, Western blotting, and immunohistochemistry were performed to evaluate cognitive function, oxidative stress, cholinergic activity, synaptic plasticity, and neuroinflammation. Results: In vitro, SH-SY5Y cells exposed to amyloid-beta (Aβ) were treated with vibrotactile stimulation, resulting in enhanced neuronal marker expression at 2.2 m/s². In vivo, mice receiving stimulation at 2.2 m/s² showed improved cognitive performance, reduced oxidative stress, restored cholinergic function, suppressed neuroinflammation, and enhanced synaptic plasticity. Mechanistically, these effects were associated with activation of the AKT/GSK3β/β-catenin pathway. Conclusions: Our findings demonstrate that vibrotactile gamma stimulation at 2.2 m/s² exerts greater therapeutic efficacy than higher acceleration, highlighting the importance of optimizing stimulation parameters. This work supports the potential of acceleration-tuned, non-invasive GENUS-based therapies as effective strategies for cognitive recovery in neurodegenerative conditions.

Major depressive disorder (MDD) involves dysregulation of the hypothalamic–pituitary–adrenal axis, neuroinflammation, serotonergic dysfunction, and impaired neurotrophic signaling. Whether combining corticosterone (CORT) with chronic restraint stress (CRS) produces a more comprehensive depression-like phenotype than either model alone remains unexplored. Male C57BL/6N mice were assigned to four groups—Sham (n = 7), CORT (20 mg/kg s.c.; n = 7), CRS (3 h/day; n = 7), and CORT + CRS (C+C; n = 8)—and evaluated by behavioral tests, hippocampal qRT-PCR, Western blot, LC-MS/MS metabolomics, and immunohistochemistry. All experimental groups showed elevated immobility in tail suspension and forced swim tests without inter-group differences. Two-way ANOVA revealed a behavioral–molecular dissociation: FST immobility showed CORT and CRS main effects without a significant interaction, whereas hippocampal LC-MS/MS analytes exhibited strong CORT × CRS interactions. The C+C group showed the strongest 5-HT1A receptor (HTR1A) upregulation, the greatest reductions in Trk-b and DCX, and unique decreases in serum dopamine, glutamine, and adenosine. Representative Western blot densitometry indicated the largest p-ERK/ERK reduction in C+C (54%), while p-CREB/CREB was most suppressed in CRS (52%). BDNF and NeuN proteins were lowest in C+C (68% and 61% reductions). Combined CORT + CRS produces the most comprehensive depression-related molecular profile, integrating multiple pathological domains.